Your browser doesn't support javascript.
loading
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Trapè, Giulio; De Angelis, Gioia; Morucci, Marco; Tarnani, Michela; De Gregoris, Cinzia; Di Veroli, Ambra; Panichi, Valentina; Topini, Giuseppe; Bassi, Loredana; Isidori, Raffaella; Poscente, Monica; Innocenti, Vincenza; Cippitelli, Elisa Emanueli; Talucci, Roberta; Bertelli, Silvia; Crocicchia, Alessandra; Lippi, Annalisa; Pezzuti, Giulia; Fuschino, Michela; Randi, Raffaella; Mastini, Cristina; Ciambella, Silvia; Pessina, Gloria; Montanaro, Marco; Latagliata, Roberto.
Affiliation
  • Trapè G; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • De Angelis G; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Morucci M; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Tarnani M; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • De Gregoris C; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Di Veroli A; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Panichi V; Laboratory of Immunophenotyping-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Topini G; Laboratory of Immunophenotyping-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Bassi L; Laboratory of Medical Genetics-ASL Viterbo, Ospedale Belcolle, Viterbo, Italy.
  • Isidori R; Laboratory of Medical Genetics-ASL Viterbo, Ospedale Belcolle, Viterbo, Italy.
  • Poscente M; Laboratory of Medical Genetics-ASL Viterbo, Ospedale Belcolle, Viterbo, Italy.
  • Innocenti V; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Cippitelli EE; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Talucci R; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Bertelli S; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Crocicchia A; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Lippi A; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Pezzuti G; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Fuschino M; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Randi R; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Mastini C; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Ciambella S; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Pessina G; Laboratory of Medical Genetics-ASL Viterbo, Ospedale Belcolle, Viterbo, Italy.
  • Montanaro M; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Latagliata R; Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
Eur J Haematol ; 111(2): 311-317, 2023 Aug.
Article in En | MEDLINE | ID: mdl-37231885
ABSTRACT

OBJECTIVES:

Aim of the study was to evaluate the role of a Domiciliary Hematologic Care Unit (DHCU) compared to standard DH setting in the active frontline treatment with hypomethylating agents (HMAs) +/- venetoclax of frail patients with acute myelogenous leukemia/high-risk myelodysplastic syndromes (AML/HR-MDS).

METHODS:

All patients with newly diagnosed AML/HR-MDS unfit for intensive care and treated frontline with HMAs from January 2010 to April 2021 were retrospectively included.

RESULTS:

Among 112 patients (62 AML/50 HR-MDS), 69 (61.6%) were treated in a standard DH setting and 43 (38.4%) were followed by DHCU, allocated to DH or DHCU by responsible physician. Overall response rate was 29/69 (42.0%) in DH versus 19/43 (44.1%) in DHCU (p = .797). Median response duration was 8.7 months (95%CI 7.0-10.3) in DH versus 13.0 months (95%CI 8.3-17.6) in DHCU (p = .460). Infections were also equally reported. Median overall survival of patients treated in DH was 13.7 months (95%CI 9.9-17.4) compared to 13.0 months (95%CI 6.7-19.3) of patients managed by DHCU (p = .753).

CONCLUSIONS:

Home care management of HMA is feasible and effective, with results similar to standard DH

setting:

this approach is thus adequate to offer active therapies in frail patients with AML/HR-MDS considered up to now ineligible.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: